TRACON Pharmaceuticals, Inc.
TCON · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $12 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $12 | -$0 | $0 | -$0 |
| % Margin | 99.9% | – | 96% | – |
| R&D Expenses | $12 | $14 | $11 | $8 |
| G&A Expenses | $7 | $14 | $18 | $8 |
| SG&A Expenses | $7 | $14 | $18 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $19 | $28 | $29 | $16 |
| Operating Income | -$7 | -$28 | -$28 | -$16 |
| % Margin | -57.3% | – | -8,192.8% | – |
| Other Income/Exp. Net | $3 | -$1 | -$0 | -$1 |
| Pre-Tax Income | -$4 | -$29 | -$29 | -$17 |
| Tax Expense | $0 | $0 | $0 | $1 |
| Net Income | -$4 | -$29 | -$29 | -$17 |
| % Margin | -29.8% | – | -8,302.3% | – |
| EPS | -2.2 | -28.02 | -33.3 | -38.63 |
| % Growth | 92.1% | 15.9% | 13.8% | – |
| EPS Diluted | -2.19 | -28.02 | -33.3 | -38.57 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $1 |
| Interest Expense | $7 | $1 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$28 | -$28 | -$16 |
| % Margin | -57.2% | – | -8,188.7% | – |